Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema

Summary

Randomized double-blind/placebo study to evaluate the efficacy of ASN002 in subjects with severe chronic hand eczema.

Timeline

Start

2019-01-03

Primary completion

2020-04-29

Completion

2020-04-29

Outcome

Met primary endpoint

release “NCT03728504). The topline results show that gusacitinib achieved a dose-dependent, clinically meaningful, and statistically significant improvement relative to placebo in both the primary” asanabio.com ↗

Publications

• Bar J, Del Duca E, David E, Bose S, Chefitz G, Brunner PM, Bissonnette R, Guttman-Yassky E. Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic Dermatitis. Allergy. 2025 Aug;80(8):2271-2285. doi: 10.1111/all.16466. Epub 2025 Jan 6.

Drugs

Indications